Robert Iannone, Executive Vice President, Global Head of Research and Development and Chief Medical Officer, on August 27, 2026, sold 76,921 shares in Jazz Pharmaceuticals (JAZZ) for $19,207,098. Following the Form 4 filing with the SEC, Iannone has control over a total of 65,686 ordinary shares of the company, with 65,686 shares held directly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1232524/000173732926000016/xslF345X05/edgardoc.xml
Joseph Michael DePinto, Director, on August 28, 2026, sold 25,000 shares in Brinker International (EAT) for $5,759,750. Following the Form 4 filing with the SEC, DePinto has control over a total of 77,812 common shares of the company, with 77,812 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/703351/000119312526377137/xslF345X05/ownership.xml
Olivier Le Peuch, Director, Chief Executive Officer, on August 31, 2026, sold 5,000 shares in SLB (SLB) for $300,000. Following the Form 4 filing with the SEC, Le Peuch has control over a total of 1,331,328 common shares of the company, with 1,331,328 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/87347/000008734726000120/xslF345X05/form4.xml
John B. Spath, Executive Vice President and Head of Operations, on August 27, 2026, sold 90,000 shares in Talos Energy (TALO) for $1,521,000. Following the Form 4 filing with the SEC, Spath has control over a total of 178,788 common shares of the company, with 178,788 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1724965/000119312526377043/xslF345X05/ownership.xml